1. Chronic pain: an increasing and urgent global burden
Chronic pain imposes the greatest loss of productivity of any health condition, creating a major threat to human capital, to achievement of targets for the sustainable development goals (https://www.un.org/sustainabledevelopment/sustainable-development-goals/), and to healthy ageing.6,28 Chronic pain disproportionally affects the most vulnerable in low- and middle-income countries (LMICs),23,25 creating a vicious cycle of poverty from the significant physical, social, psychological, occupational, and financial sequelae of pain. Critically, the burden of pain, particularly musculoskeletal pain, continues to rise globally.7,23 The pooled prevalence estimate for chronic pain of any origin in adults in the United Kingdom is 43.5%, and about one in 10 live with chronic widespread pain.13 Prevalence estimates are associated with older age (eg, up to 62% among individuals >75 years), highlighting important implications for population ageing globally.6,32 These estimates and trends mirror those from LMICs.22
2. Addressing chronic pain in health systems
The global relevance of pain and the scale of its burden justify urgent global leadership in driving quality pain care that includes preventive public health and optimizing service delivery for people living with pain. The World Health Organization, IASP, and other political, government, and civil society organizations have the opportunity to drive global system-strengthening initiatives. These system-level initiatives incorporate the fundamental building blocks of health and social care systems: policy and regulation, financing models, workforce planning, information systems, and mechanisms for optimal service delivery. At a population level, these critical building blocks facilitate accessibility, safety, effectiveness, and sustainability of pain care. Such strategies are typically created and operationalized by system-level managers (eg, policy makers) and administrators within health services. Despite the personal and societal impacts of chronic pain, few nations, particularly LMICs,16 have developed appropriate system-level strategies to address the impact, and to support delivery, of appropriate pain care. This landscape highlights the need for system-level strengthening initiatives that explicitly consider pain,6,25 and particularly in LMICs.18,25 Initiatives such as the World Health Organization Rehabilitation 2030 (http://www.who.int/disabilities/care/rehab-2030/en/) and Integrated Care for Older People (https://www.who.int/ageing/health-systems/icope/en/) offer promising levers to integrate pain care into contemporary global system-strengthening approaches.4
3. Value-based care for chronic musculoskeletal pain in health systems
Despite the increasing burden of chronic musculoskeletal pain,23 access to safe and effective care (high-value care) globally remains highly variable. Elshaug et al.12 define high-value care as “care for which evidence suggests it confers benefit to patients, or probability of benefit exceeds probable harm.” Conversely, low-value care is defined as “care for which evidence suggests it confers no or very little benefit to patients, or risk of harm exceeds probable benefit.”
Although clinical guidelines and Models of Care (system-level frameworks that guide service delivery for specific conditions5) recommend high-value options as preventive public health strategies and first-line treatments (eg, exercise and weight loss for osteoarthritis pain), many health systems fail to achieve this: delivering too much low-value pain care and too little high-value pain care. Public health initiatives and care pathways for people with established conditions must be supported by policy and financing models that emphasise first-line, effective interventions, while also respecting patient preferences, cultural and ethnic sensitivities, and capacity for tailoring care. For example, the feasibility of implementing high-value pain care is being assessed in LMICs, such as in Nepal.29
Ironically, citizens of high-income economies can access low-value care options, whereas those in LMICs have limited or no access to appropriate pain care, eg analgesia for pain relief.25,33 The use of opioids for managing noncancer musculoskeletal pain is widespread and yet, with few exceptions, is discordant with evidence in most situations and has great potential for harm.26 Other low-value care examples commonly delivered for musculoskeletal pain include: routine spinal imaging in the absence of specific indicators and spinal fusion surgery for nonspecific low back pain15; arthroscopic surgery as primary treatment for knee joint osteoarthritis30; vertebroplasty for osteoporotic vertebral fracture9; and overuse of passive therapies, including analgesic medicines and conservative therapies (eg, manual and electrotherapies), in the absence of appropriate active self-management.3 Funding low-value care options can increase risk of harm, restrict opportunities for improvements in health outcomes that may otherwise be achievable with higher-value care options, and limit funding of, and access to, higher-value care options.8 High-value care examples for musculoskeletal pain include contemporary education about pain, addressing unhelpful beliefs, providing reassurance, reducing distress, promoting graded functional activities, supporting return to work, and where appropriate, behavioural therapies and nutritional care.2 Surgery, medicines, and other interventions may represent high-value care in appropriately selected patients, (eg, total joint replacement surgery, disease-modifying medicines for inflammatory arthritides, opioids for postsurgical pain, and emergency surgery for cauda equina compression). Systems should support timely delivery of these interventions where and when appropriate.
4. Drivers of low-value pain care
Drivers of low-value pain care are complex and interdependent. First, the traditional biomedical model of pain focuses on a target tissue “to be fixed.” This model is discordant with the contemporary biopsychosocial model of pain. The biomedical model fails to capture the multidimensional contributors to each individual’s experience of pain. Clinicians’ belief in this model and system- and service-level support for a biomedical model may drive behaviours that favour low-value therapeutic pathways that may be more heavily marketed, easier to access, and simpler to understand, but less likely to provide long-term benefit for most.
Second, many low-value diagnostic and therapeutic approaches are delivered in a short time frame, at high cost. Depending on the financing models of different health care settings, these approaches can present attractive options that are profitable for clinicians and health facilities (by generating high throughput and high revenue), creating opportunities for subconscious or conscious bias towards low-value care. Although high-value interventions are often less expensive per unit than many low-value approaches, they are often more difficult to access because current funding models limit opportunities to deliver high-value care options at scale. Access may also be constrained by limited clinician training in high-value care approaches, such as psychologically informed care.31
Third, commercial entities have exerted undue influence over clinical behaviours and consumer preferences, as well as over regulatory policies. The opioid epidemic in the United States and other nations highlights the ways in which the pharmaceutical industry has partially shaped the discourse on pain management. Pharmaceutical companies were reported to have spent $USD 880 million on political contributions and lobbying efforts from 2006 to 2015, and opioid medicine claims have been associated with benefits received by physicians from industry.17,20 A confluence of factors, in high-income settings and LMICs,20 has created a perfect low-value care climate: direct marketing to patients in a consumerist society; physician benefits in a landscape of comparatively loose regulations for prescribing; active influence of medical societies to promote widespread use of prescription opioids; and aggressive lobbying to maintain comparatively less stringent regulation in terms of price setting and marketing restrictions.20
5. System strengthening to promote high-value pain care
Governments and health services need to invest in high-value care while concurrently disinvesting in low-value or no-value care, inclusive of preventive public health initiatives. Such a reorientation is likely to produce a major return on investment for national economic development necessary to meet sustainable development goal targets,24 to overcome commercial and economic drivers to low-value pain care,12 and to support access to affordable and effective pain care. Multiple strategies are required to achieve such reorientation.7,10,25,27 First, at a system level, development of appropriate policy and regulation are needed to prioritise high-value pain care (eg, National Pain Strategies, such as those developed in Australia1 and the United States21 and pain Models of Care5). Regulation must include financing arrangements to defund ineffective and potentially harmful diagnostics and interventions and incentivise high-value, integrated care. The amendment of physician payment schedules instituted in Ontario, Canada, in 2012 to reflect evidence-informed care for low back pain is one such system-level example (http://www.health.gov.on.ca/en/pro/programs/ecfa/action/primary/lower_back.aspx). Although condition-specific strategies may be more feasible in high-income settings, integration of pain care reforms into existing health system infrastructure will be particularly important for LMICs. Supporting integration between health and social care services will be essential to address pain in the context of healthy ageing and chronic condition management.4 Policy and financing reform are also essential to develop and implement downstream surveillance systems (eg, pain registries and population pain prevalence monitoring, particularly in LMICs19), pain care standards, and pathways linked to reimbursement at a service level for public and private health services and insurance schemes. Linking service delivery performance with funding and measuring outcomes will help better inform consumers’ knowledge, drive improved clinical practice behaviours, and reduce variability in delivery of high-value care. A range of models exists for regulation of and/or cooperation with private industry to achieve health gains.11 Engagement with the private sector through appropriately administered and regulated partnerships is essential to develop and implement appropriate policy and regulation for pain care and public health generally.
Second, building capacity in health practitioners’ and emerging practitioners’ knowledge and interprofessional skills of a contemporary understanding of pain science is vital (http://www.iasp-pain.org/GlobalYear). This includes highlighting the need for integration of pain care within and across training curricula, supporting interdisciplinary care consistent with core competencies,14 and achieving balance between commercial and noncommercial providers of professional development.
Third, building and evaluating pain literacy and awareness of value-based care among consumers and civil society will help to ensure that people can actively and effectively participate in their care decisions, health reform debates, and processes to inform pain care.
Acknowledgements
A.M. Briggs is supported by part-time fellowships awarded by the Australian National Health and Medical Research Council (#1132548) and the Global Alliance for Musculoskeletal Health with funding from the International League of Associations for Rheumatology and Curtin University, Australia. Dr Hsieh is supported by NIH/Fogarty International Center K01TW009995, the Yale Center for Clinical Investigation/Doris Duke Foundation Fund to Retain Clinical Scientists, and has previously received honoraria from Gilead.
Footnotes
Conflict of interest statement
The authors have no conflicts of interest to declare.
References
- [1].Australian and New Zealand College of Anaesthetists. National Pain Strategy. Melbourne: Faculty of Pain Medicine, 2010. [Google Scholar]
- [2].Babatunde OO, Jordan JL, Van der Windt DA, Hill JC, Foster NE, Protheroe J. Effective treatment options for musculoskeletal pain in primary care: a systematic overview of current evidence. PLoS One 2017;12:e0178621. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [3].Blyth FM, March LM, Nicholas MK, Cousins MJ. Self-management of chronic pain: a population-based study. PAIN 2005;113:285–92. [DOI] [PubMed] [Google Scholar]
- [4].Briggs AM, Araujo de Carvalho I. Actions required to implement integrated care for older people in the community using the World Health Organization’s ICOPE approach: a global Delphi consensus study. PLoS One 2018;13:e0205533. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [5].Briggs AM, Chan M, Slater H. Models of Care for musculoskeletal health: moving towards meaningful implementation and evaluation across conditions and care settings. Best Pract Res Clin Rheumatol 2016;30:359–74. [DOI] [PubMed] [Google Scholar]
- [6].Briggs AM, Cross MJ, Hoy DG, Sanchez-Riera L, Blyth FM, Woolf AD, March L. Musculoskeletal health conditions represent a global threat to healthy aging: a report for the 2015 World Health Organisation World Report on Ageing and Health. Gerontologist 2016;56(suppl 2):S234–55. [DOI] [PubMed] [Google Scholar]
- [7].Briggs AM, Woolf AD, Dreinhoefer KE, Homb N, Hoy DG, Kopansky-Giles D, Akesson K, March L. Reducing the global burden of musculoskeletal conditions. Bull World Health Organ 2018;96:366–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [8].Brownlee S, Chalkidou K, Doust J, Elshaug AG, Glasziou P, Heath I, Nagpal S, Saini V, Srivastava D, Chalmers K, Korenstein D. Evidence for overuse of medical services around the world. Lancet 2017;390:156–68. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [9].Buchbinder R, Golmohammadi K, Johnston RV, Owen RJ, Homik J, Jones A, Dhillon SS, Kallmes DF, Lambert RGW. Percutaneous vertebroplasty for osteoporotic vertebral compression fracture. Cochrane Database Syst Rev 2015:CD006349. [DOI] [PubMed] [Google Scholar]
- [10].Buchbinder R, van Tulder M, Oberg B, Costa LM, Woolf A, Schoene M, Croft P; Lancet Low Back Pain Series Working Group. Low back pain: a call for action. Lancet 2018;391:2384–8. [DOI] [PubMed] [Google Scholar]
- [11].Buse K, Tanaka S, Hawkes S. Healthy people and healthy profits? Elaborating a conceptual framework for governing the commercial determinants of non-communicable diseases and identifying options for reducing risk exposure. Glob Health 2017;13:34. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [12].Elshaug AG, Rosenthal MB, Lavis JN, Brownlee S, Schmidt H, Nagpal S, Littlejohns P, Srivastava D, Tunis S, Saini V. Levers for addressing medical underuse and overuse: achieving high-value health care. Lancet 2017;390:191–202. [DOI] [PubMed] [Google Scholar]
- [13].Fayaz A, Croft P, Langford RM, Donaldson LJ, Jones GT. Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies. BMJ Open 2016;6:e010364. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [14].Fishman SM, Young HM, Lucas Arwood E, Chou R, Herr K, Murinson BB, Watt-Watson J, Carr DB, Gordon DB, Stevens BJ, Bakerjian D, Ballantyne JC, Courtenay M, Djukic M, Koebner IJ, Mongoven JM, Paice JA, Prasad R, Singh N, Sluka KA, St Marie B, Strassels SA. Core competencies for pain management: results of an interprofessional consensus summit. Pain Med 2013;14:971–81. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [15].Foster NE, Anema JR, Cherkin D, Chou R, Cohen SP, Gross DP, Ferreira PH, Fritz JM, Koes BW, Peul W, Turner JA, Maher CG; Lancet Low Back Pain Series Working Group. Prevention and treatment of low back pain: evidence, challenges, and promising directions. Lancet 2018;391:2368–83. [DOI] [PubMed] [Google Scholar]
- [16].Goucke CR, Chaudakshetrin P. Pain: a neglected problem in the low-resource setting. Anesth Analg 2018;126:1283–6. [DOI] [PubMed] [Google Scholar]
- [17].Hadland SE, Cerda M, Li Y, Krieger MS, Marshall BDL. Association of pharmaceutical industry marketing of opioid products to physicians with subsequent opioid prescribing. JAMA Intern Med 2018;178:861–3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [18].Hoy D, Geere JA, Davatchi F, Meggitt B, Barrero LH. A time for action: opportunities for preventing the growing burden and disability from musculoskeletal conditions in low- and middle-income countries. Best Pract Res Clin Rheumatol 2014;28:377–93. [DOI] [PubMed] [Google Scholar]
- [19].Hoy DG, Raikoti T, Smith E, Tuzakana A, Gill T, Matikarai K, Tako J, Jorari A, Blyth F, Pitaboe A, Buchbinder R, Kalauma I, Brooks P, Lepers C, Woolf A, Briggs A, March L. Use of the Global Alliance for Musculoskeletal Health survey module for estimating the population prevalence of musculoskeletal pain: findings from the Solomon Islands. BMC Musculoskelet Disord 2018;19:292. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [20].Humphreys K Avoiding globalisation of the prescription opioid epidemic. Lancet 2017;390:437–9. [DOI] [PubMed] [Google Scholar]
- [21].Institute of Medicine (IOM). Relieving pain in America: a blueprint for transforming prevention, care, education, and research. Washington: The National Academies Press, 2011. [PubMed] [Google Scholar]
- [22].Jackson T, Thomas S, Stabile V, Shotwell M, Han X, McQueen K. A systematic review and meta-analysis of the global burden of chronic pain without clear etiology in low and middle-income countries: trends in heterogeneous data and a proposal for new assessment methods. Anesth Analg 2016;123:739–48. [DOI] [PubMed] [Google Scholar]
- [23].James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, Abbastabar H, Abd-Allah F, Abdela J, Abdelalim A, Abdollahpour I, Abdulkader RS, Abebe Z, Abera SF, Abil OZ, Abraha HN, Abu-Raddad LJ, Abu-Rmeileh NME, Accrombessi MMK, Acharya D, Acharya P, Ackerman IN, Adamu AA, Adebayo OM, Adekanmbi V, Adetokunboh OO, Adib MG, Adsuar JC, Afanvi KA, Afarideh M, Afshin A, Agarwal G, Agesa KM, Aggarwal R, Aghayan SA, Agrawal S, Ahmadi A, Ahmadi M, Ahmadieh H, Ahmed MB, Aichour AN, Aichour I, Aichour MTE, Akinyemiju T, Akseer N, Al-Aly Z, Al-Eyadhy A, Al-Mekhlafi HM, Al-Raddadi RM, Alahdab F, Alam K, Alam T, Alashi A, Alavian SM, Alene KA, Alijanzadeh M, Alizadeh-Navaei R, Aljunid SM, Alkerwi A, Alla F, Allebeck P, Alouani MML, Altirkawi K, Alvis-Guzman N, Amare AT, Aminde LN, Ammar W, Amoako YA, Anber NH, Andrei CL, Androudi S, Animut MD, Anjomshoa M, Ansha MG, Antonio CAT, Anwari P, Arabloo J, Arauz A, Aremu O, Ariani F, Armoon B, Arnlov J, Arora A, Al A, Aryal KK, Asayesh H, Asghar RJ, Ataro Z, Atre SR, Ausloos M, Avila-Burgos L, Avokpaho E, Awasthi A, Quintanilla BPA, Ayer R, Azzopardi PS, Babazadeh A, Badali H, Badawi A, Bali AG, Ballesteros KE, Ballew SH, Banach M, Banoub JAM, Banstola A, Barac A, Barboza MA, Barker-Collo SL, Barnighausen TW, Barrero LH, Baune BT, Bazargan-Hejazi S, Bedi N, Beghi E, Behzadifar M, Behzadifar M, Bejot Y, Belachew AB, Belay YA, Bel ML, Bello AK, Bensenor IM, Bernabe E, Bernstein RS, Beuran M, Beyranvand T, Bhala N, Bhattarai S, Bhaumik S, Bhutta ZA, Biadgo B, Bijani A, Bikbov B, Bilano V, Bililign N, Bin Sayeed MS, Bisanzio D, Blacker BF, Blyth FM, Bou-Orm IR, Boufous S, Bourne R, Brady OJ, Brainin M, Brant LC, Brazinova A, Breitborde NJK, Brenner H, Briant PS, Briggs AM, Briko AN, Britton G, Brugha T, Buchbinder R, Busse R, Butt ZA, Cahuana-Hurtado L, Cano J, Cardenas R, Carrero JJ, Carter A, Carvalho F, Castaneda-Orjuela CA, Rivas JC, Castro F, Catala-Lopez F, Cercy KM, Cerin E, Chaiah Y, Chang AR, Chang HY, Chang JC, Charlson FJ, Chattopadhyay A, Chattu VK, Chaturvedi P, Chiang PPC, Chin KL, Chitheer A, Choi JYJ, Chowdhury R, Christensen H, Christopher DJ, Cicuttini FM, Ciobanu LG, Cirillo M, Claro RM, Collado-Mateo D, Cooper C, Coresh J, Cortesi PA, Cortinovis M, Costa M, Cousin E, Criqui MH, Cromwell EA, Cross M, Crump JA, Dadi AF, Dandona L, Dandona R, Dargan PI, Daryani A, Das Gupta R, Das Neves J, Dasa TT, Davey G, Davis AC, Davitoiu DV, De Courten B, De La Hoz FP, De Leo D, De Neve JW, Degefa MG, Degenhardt L, Deiparine S, Dellavalle RP, Demoz GT, Deribe K, Dervenis N, Jarlais DCD, Dessie GA, Dey S, Dharmaratne SD, Dinberu MT, Dirac MA, Djalalinia S, Doan L, Dokova K, Doku DT, Dorsey ER, Doyle KE, Driscoll TR, Dubey M, Dubljanin E, Duken EE, Duncan BB, Duraes AR, Ebrahimi H, Ebrahimpour S, Echko MM, Edvardsson D, Effiong A, Ehrlich JR, El Bcheraoui C, Zaki MES, El-Khatib Z, Elkout H, Elvazar IRF, Enayati A, Endries AY, Er B, Erskine HE, Eshrati B, Eskandarieh S, Esteghamati A, Esteghamati S, Fakhim H, Omrani VF, Faramarzi M, Fareed M, Farhadi F, Farid TA, Farinha C, Farioli A, Faro A, Farvid MS, Farzadfar F, Feigin VL, Fentahun N, Fereshtehnejad SM, Fernandes E, Fernandes JC, Ferrari AJ, Feyissa GT, Filip I, Fischer F, Fitzmaurice C, Foigt NA, Foreman KJ, Fox J, Frank TD, Fukumoto T, Fullman N, Furst T, Furtado JM, Futran ND, Gall S, Ganji M, Gankpe FG, Garcia-Basteiro AL, Gardner WM, Gebre AK, Gebremedhin AT, Gebremichael TG, Gelano TF, Geleijnse JM, Genova-Maleras R, Geramo YCD, Gething PW, Gezae KE, Ghadiri K, Falavarjani KG, Ghasemi-Kasman M, Ghimire M, Ghosh R, Ghoshal AG, Giampaoli S, Gill PS, Gill TK, Ginawi IA, Giussani G, Gnedovskaya EV, Goldberg EM, Goli S, Gomez-Dantes H, Gona PN, Gopalani SV, Gorman TM, Goulart AC, Goulart BNG, Grada A, Grams ME, Grosso G, Gugnani HC, Guo YM, Gupta PC, Gupta R, Gupta R, Gupta T, Gyawali B, Haagsma JA, Hachinski V, Hafezi-Nejad N, Bidgoli HH, Hagos TB, Hailu GB, Haj-Mirzaian A, Haj-Mirzaian A, Hamadeh RR, Hamidi S, Handal AJ, Hankey GJ, Hao YT, Harb HL, Harikrishnan S, Haro JM, Hasan M, Hassankhani H, Hassen HY, Havmoeller R, Hawley CN, Hay RJ, Hay SI, Hedayatizadeh-Omran A, Heibati B, Hendrie D, Henok A, Herteliu C, Heydarpour S, Hibstu DT, Hoang HT, Hoek HW, Hoffman HJ, Hole MK, Rad EH, Hoogar P, Hosgood HD, Hosseini SM, Hosseinzadeh M, Hostiuc M, Hostiuc S, Hotez PJ, Hoy DG, Hsairi M, Htet AS, Hu GQ, Huang JJ, Humh CK, Iburg KM, Ikeda CT, Ileanu B, Ilesanmi OS, Iqbal U, Irvani SSN, Irvine CMS, Islam SMS, Islami F, Jacobsen KH, Jahangiry L, Jahanmehr N, Jain SK, Jalkovnevic M, Javanbakht M, Jayatilleke AU, Jeemon P, Jha RP, Jha V, Ji JS, Johnson CO, Jonas JB, Jozwiak JJ, Jungari SB, Jurisson M, Kabir Z, Kadel R, Kahsay A, Kalani R, Kanchan T, Karami M, Matin BK, Karch A, Karema C, Karimi N, Karimi SM, Kasaeian A, Kassa DH, Kassa GM, Kassa TD, Kassebaum NJ, Katikireddi SV, Kawakami N, Karyani AK, Keighobadi MM, Keiyoro PN, Kemmer L, Kemp GR, Kengne AP, Keren A, Khader YS, Khafaei B, Khafaie MA, Khajavi A, Khalil IA, Khan EA, Khan MS, Khan MA, Khang YH, Khazaei M, Khoja AT, Khosravi A, Khosravi MH, Kiadaliri AA, Kiirithio DN, Kim CI, Kim D, Kim P, Kim YE, Kim YJ, Kimokoti RW, Kinfu Y, Kisa A, Kissimova-Skarbek K, Kivimaki M, Knudsen AKS, Kocarnik JM, Kochhar S, Kokubo Y, Kolola T, Kopec JA, Kosen S, Kotsakis GA, Koul PA, Koyanagi A, Kravchenko MA, Krishan K, Krohn KJ, Defo BK, Bicer BK, Kumar GA, Kumar M, Kyu HH, Lad DP, Lad SD, Iofranconi A, Lalloo R, Lallukka T, Lami FH, Lansingh VC, Latifi A, Lau KMM, Lazarus JV, Leasher JL, Ledesma JR, Lee PH, Leigh J, Leung J, Levi M, Lewycka S, Li SS, Li YC, Liao Y, Liben MI, Lim LL, Lim SS, Liu SW, Lodha R, Looker KJ, Lopez AD, Lorkowski S, Lotufo PA, Low N, Lozano R, Lucas TCD, Lucchesi LR, Lunevicius R, Lyons RA, Ma S, Macarayan ERK, Mackay MT, Madotto F, Abd El Razelk HM, Abd El Razek MM, Maghavani DP, Malootra NB, Mai HT, Majdan M, Majdzadeh R, Majeed A, Malekzadeh R, Malta DC, Mamun AA, Manda AL, Manguerra H, Manhertz T, Mansournia MA, Mantovani LG, Mapoma CC, Maravilla JC, Marcenes W, Marks A, Martins-Melo FR, Martopullo I, Marz W, Marzan MB, Mashamba-Thompson TP, Massenburg BB, Mathur MR, Matsushita K, Maulik PK, Mazidi M, McAlinden C, McGrath JJ, McKee M, Mehndiratta MM, Mehrotra R, Mehta KV, Mehta V, Mejia-Rodriguez F, Mekonen T, Melese A, Melku M, Meltzer M, Memiah PTN, Memish ZA, Mendoza W, Mengistu DT, Mengistu G, Mensah GA, Mereta ST, Meretoja A, Meretoja TJ, Mestrovic T, Mezerji NMG, Miazgowski B, Miazgowski T, Millear AI, Miller TR, Miltz B, Mini GK, Mirarefin M, Minakhimov EM, Misganaw AT, Mitchell PB, Mitiku H, Moazen B, Mohajer B, Mohammad KA, Mohammadifard N, Mohammadnia-Afrouzi M, Mohammed MA, Mohammed S, Mohebi F, Moitra M, Mokdad AH, Molokhia M, Monasta L, Moodley Y, Moosazadeh M, Moradi G, Moradi-Lakeh M, Moradinazar M, Moraga P, Morawska L, Velasquez IM, Morgado-Da-Costa J, Morrison SD, Moschos MM, Mousavi SM, Mruts KB, Muche AA, Muchie KF, Mueller UO, Mohammed OS, Mukhopadhyay S, Muller K, Mumford JE, Murhekar M, Musa J, Musa KI, Mustafa G, Nabhan AF, Nagata C, Naghavi M, Naheed A, Nahvijou A, Naik G, Naik N, Najah F, Naldi L, Nam HS, Nangia V, Nansseu JR, Nascimento BR, Natarajan G, Neamati N, Negoi I, Negoi RI, Neupane S, Newton CRJ, Ngunjiri JW, Nguyen AQ, Nguyen HT, Nguyen HLT, Nguyen HT, Nguyen LH, Nguyen M, Nguyen NB, Nguyen SH, Nichols E, Ningrum DNA, Nixon MR, Nolutshungu N, Nomura S, Norheim OF, Noroozi M, Norrving B, Noubiap JJ, Nouri HR, Shiadeh MN, Nowroozi MR, Nsoesie E, Nyasulu PS, Odell CM, Ofori-Asenso R, Ogbo FA, Oh IH, Oladimeji O, Olagunju AT, Olagunju TO, Olivares PR, Olsen HE, Olusanya BO, Ong KL, Ong SK, Oren E, Ortiz A, Ota E, Otstavnov SS, Overland S, Owolabi MO, Mahesh PA, Pacella R, Pakpour AH, Pana A, Panda-Jonas S, Parisi A, Park EK, Parry CDH, Patel S, Pati S, Paint ST, Patle A, Patton GC, Paturi VR, Paulson KR, Pearce N, Pereira DM, Perico N, Pesudovs K, Pham HQ, Phillips MR, Pigott DM, Pilly JD, Piradov MA, Pirsaheb M, Pishgar F, Plana-Ripoll O, Plass D, Polinder S, Popova S, Postma MJ, Pourshams A, Poustchi H, Prabhakaran D, Prakash S, Prakash V, Purcell CA, Purwar MB, Qorbani M, Quistberg DA, Radfar A, Rafay A, Rafiei A, Rahim F, Rahimi K, Rahimi-Movaghar A, Rahimi-Movaghar V, Rahman M, Rahman MHU, Rahman MA, Rahman SU, Rai RK, Rajati F, Ram U, Ranjan P, Ranta A, Rao PC, Rawaf DL, Rawaf S, Reddy KS, Reiner RC, Reinig N, Reitsma MB, Remuzzi G, Renzaho AMN, Resnikoff S, Rezaei S, Rezai MS, Ribeiro ALP, Robinson SR, Roever L, Ronfani L, Roshandel G, Rostami A, Roth GA, Roy A, Rubagotti E, Sachdev PS, Sadat N, Saddik B, Sadeghi E, Moghaddam SS, Safari H, Safari Y, Safari-Faramani R, Safdarian M, Safi S, Safiri S, Sagar R, Sahebkar A, Sahraian MA, Sajadi HS, Salam N, Salama JS, Salamati P, Saleem K, Saleem Z, Salimi Y, Salomon JA, Salvi SS, Sale I, Samy AM, Sanabria J, Sang YY, Santomauro DF, Santos IS, Santos JV, Milicevic MMS, Jose BPS, Sardana M, Sarker AR, Sarrafzadegan N, Sartorius B, Sarvi S, Sathian B, Satpathy M, Sawant AR, Sawhney M, Saxena S, Saylan M, Schaeffner E, Schmidt MI, Schneider IJC, Schottker B, Schwebel DC, Schwendicke F, Scott JG, Sekerija M, Sepanlou SG, Servan-Mori E, Seyedmousavi S, Shabaninejad H, Shafieesabet A, Shahbazi M, Shaheen AA, Shaikh MA, Shams-Beyranvand M, Shamsi M, Shamsizadeh M, Sharafi H, Sharafi K, Sharif M, Sharif-Alhoseini M, Sharma M, Sharma R, She J, Sheikh A, Shi P, Shibuya K, Shigematsu M, Shiri R, Shirkoohi R, Shishani K, Shiue I, Shokraneh F, Shoman H, Shrime MG, Si S, Siabani S, Siddiqi TJ, Sigfusdottir ID, Sigurvinsdottir R, Silva JP, Silveira DGA, Singam NSV, Singh JA, Singh NP, Singh V, Sinha DN, Skiadaresi E, Slepak ELN, Sliwa K, Smith DL, Smith M, Soares AM, Sobaih BH, Sobhani S, Sobngwi E, Soneji SS, Soofi M, Soosaraei M, Sorensen RJD, Soriano JB, Soyiri IN, Sposato LA, Sreeramareddy CT, Srinivasan V, Stanaway JD, Stein DJ, Steiner C, Steiner TJ, Stokes MA, Stovner LJ, Subart ML, Sudaryanto A, Sufiyan MB, Sunguya BF, Sur PJ, Sutradhar I, Sykes BL, Sylte DO, Tabares-Seisdedos R, Tadakamadla SK, Tadesse BT, Tandon N, Tassew SG, Tavakkoli M, Taveira N, Taylor HR, Tehrani-Banihashemi A, Tekalign TG, Tekelemedhin SW, Tekle MG, Temesgen H, Temsah MH, Temsah O, Terkawi AS, Teweldemedhin M, Thankappan KR, Thomas N, Tilahun B, To QG, Tonelli M, Topor-Madry R, Topouzis F, Torre AF, Tortajada-Girbes M, Touvier M, Tovani-Palone MR, Towbin JA, Tran BX, Tran KB, Troeger CE, Truelsen TC, Tsilimbaris MK, Tsoi D, Car LT, Tuzcu EM, Ukwaja KN, Ullah I, Undurraga EA, Unutzer J, Updike RL, Usman MS, Uthman OA, Vaduganathan M, Vaezi A, Valdez PR, Varughese S, Vasankari TJ, Venketasubramanian N, Villafaina S, Violante FS, Vladimirov SK, Vlassov V, Vollset SE, Vosoughi K, Vujcic IS, Wagnew FS, Waheed Y, Waller SG, Wang YF, Wang YP, Weiderpass E, Weintraub RG, Weiss DJ, Weldegebreal F, Weldegwergs KG, Werdecker A, West TE, Whiteford HA, Widecka J, Wijeratne T, Wilner LB, Wilson S, Winkler AS, Wiyeh AB, Wiysonge CS, Wolfe CDA, Woolf AD, Wu SL, Wu YC, Wyper GMA, Xavier D, Xu GL, Yadgir S, Yadollahpour A, Jabbari SHY, Yamada T, Yan LL, Yano Y, Yaseri M, Yasin YJ, Yeshaneh A, Yimer EM, Yip P, Yisma E, Yonemoto N, Yoon SJ, Yotebieng M, Younis MZ, Yousefifard M, Yu CH, Zadnik V, Zaidi Z, Bin Zaman S, Zamani M, Zare Z, Zeleke AJ, Zenebe ZM, Zhang K, Zhao Z, Zhou MG, Zodpey S, Zucker I, Vos T, Murray CJL; GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1789–858. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [24].Jamison DT, Summers LH, Alleyne G, Arrow KJ, Berkley S, Binagwaho A, Bustreo F, Evans D, Feachem RG, Frenk J, Ghosh G, Goldie SJ, Guo Y, Gupta S, Horton R, Kruk ME, Mahmoud A, Mohohlo LK, Ncube M, Pablos-Mendez A, Reddy KS, Saxenian H, Soucat A, Ulltveit-Moe KH, Yamey G. Global health 2035: a world converging within a generation. Lancet 2013;382:1898–955. [DOI] [PubMed] [Google Scholar]
- [25].Knaul FM, Farmer PE, Krakauer EL, De Lima L, Bhadelia A, Jiang Kwete X, Arreola-Ornelas H, Gómez-Dantés O, Rodriguez NM, Alleyne GAO, Connor SR, Hunter DJ, Lohman D, Radbruch L, del Rocío Sáenz Madrigal M, Atun R, Foley KM, Frenk J, Jamison DT, Rajagopal MR, Knaul FM, Farmer PE, Abu-Saad Huijer H, Alleyne GAO, Atun R, Binagwaho A, Bošnjak SM, Clark D, Cleary JF, Cossío Díaz JR, De Lima L, Foley KM, Frenk J, Goh C, Goldschmidt-Clermont PJ, Gospodarowicz M, Gwyther L, Higginson IJ, Hughes-Hallett T, Hunter DJ, Jamison DT, Krakauer EL, Lohman D, Luyirika EBK, Medina Mora ME, Mwangi-Powell FN, Nishtar S, O’Brien ME, Radbruch L, Rajagopal MR, Reddy KS, del Rocío Sáenz Madrigal M, Salerno JA, Bhadelia A, Allende S, Arreola-Ornelas H, Bhadelia N, Calderon M, Connor SR, Fan VY, Gómez-Dantés O, Jiménez J, Ntizimira CR, Perez-Cruz PE, Salas-Herrera IG, Spence D, Steedman MR, Verguet S, Downing JD, Paudel BD, Elsner M, Gillespie JA, Hofman KJ, Jiang Kwete X, Khanh QT, Lorenz KA, Méndez Carniado O, Nugent R, Rodriguez NM, Wroe EB, Zimmerman C. Alleviating the access abyss in palliative care and pain relief—an imperative of universal health coverage: the Lancet Commission report. Lancet 2018;391:1391–454. [DOI] [PubMed] [Google Scholar]
- [26].Krebs EE, Gravely A, Nugent S, Jensen AC, DeRonne B, Goldsmith ES, Kroenke K, Bair MJ, Noorbaloochi S. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: the SPACE randomized clinical trial. JAMA 2018;319:872–82. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [27].Samet JH, Kertesz SG. Suggested paths to fixing the opioid crisis: directions and misdirections. JAMA Netw Open 2018;1:e180218. [DOI] [PubMed] [Google Scholar]
- [28].Schofield DJ, Shrestha RN, Cunich M, Tanton R, Kelly S, Passey ME, Veerman LJ. Lost productive life years caused by chronic conditions in Australians aged 45-64 years, 2010-2030. Med J Aust 2015;203:260. [DOI] [PubMed] [Google Scholar]
- [29].Sharma S, Jensen MP, Moseley GL, Abbott JH. Pain education for patients with non-specific low back pain in Nepal: protocol of a feasibility randomised clinical trial (PEN-LBP Trial). BMJ Open 2018;8:e022423. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [30].Siemieniuk RAC, Harris IA, Agoritsas T, Poolman RW, Brignardello-Petersen R, Van de Velde S, Buchbinder R, Englund M, Lytvyn L, Quinlan C, Helsingen L, Knutsen G, Olsen NR, Macdonald H, Hailey L, Wilson HM, Lydiatt A, Kristiansen A. Arthroscopic surgery for degenerative knee arthritis and meniscal tears: a clinical practice guideline. BMJ 2018:52;313. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [31].Synnott A, O’Keeffe M, Bunzli S, Dankaerts W, O’Sullivan P, O’Sullivan K. Physiotherapists may stigmatise or feel unprepared to treat people with low back pain and psychosocial factors that influence recovery: a systematic review. J Physiother 2015;61:68–76. [DOI] [PubMed] [Google Scholar]
- [32].World Health Organisation. World report on ageing and health. Geneva: WHO, 2015. [Google Scholar]
- [33].World Health Organization. Access to Controlled Medications Programme: improving access to medications under international drug conventions: briefing note. Geneva: WHO, 2009. [Google Scholar]